Keyword: Rubraca

Clovis CEO Patrick Mahaffy is making it clear he’s ready to deal—and doing what he can to make the PARP player a top M&A target.

One of Clovis's largest investors reportedly wants the company to raise its hand for a buyout as it struggles to stand out in the PARP market.

PARP drugmaker Tesaro may have had a tough time finding a buyer. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.

From nearly $190 per share when it first explored a sale to a $75 price that still upset GSK's investors, Tesaro walked a brambled path to the buyout.

Clovis is facing several challenges that have biopharma experts speculating it will be snapped up by an asset-hungry Big Pharma player.

Despite a field that features four entrants and a wealth of data supporting their use, some doctors still aren't on board with PARP inhibitors.

Earlier this month, Clovis' Rubraca won the FDA’s breakthrough tag in prostate cancer. Now, Clovis has unveiled the data that got it the distinction.

Clovis' Rubraca nabbed a breakthrough designation in prostate cancer, putting it in line for a first PARP nod in that field—and $580M in added sales.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.